Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study
Double - Blind, Randomized, single centered study. The purpose of this study is to assess the feasibility of minocycline vs. placebo, added to atypical antipsychotic medications, for positive symptoms in adults suffering from schizophrenia.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
- Positive symptoms [ Time Frame: from baseline to the end of the study (day 56) ] [ Designated as safety issue: No ]Positive symptoms: The change in Scale for the Positive and Negative Syndrome Scale (PANSS) score from baseline to the end of the study and the change in Clinical Global Impression Scale (CGI).
|Study Start Date:||June 2010|
|Estimated Study Completion Date:||January 2013|
|Estimated Primary Completion Date:||January 2013 (Final data collection date for primary outcome measure)|
minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
|Placebo Comparator: Placebo||
placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.
From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.
|Contact: yechiel levkovitz, MD, PhDemail@example.com|
|shalvata MHC||Not yet recruiting|
|Hod HAsharon, Israel|
|Contact: yechiel levkovitz 972-9-7478644|
|Principal Investigator: yechiel levkovitz, MD, PhD|
|Shalvata Mental Health Center||Recruiting|
|Hod Hasharon, Israel|
|Contact: Hilik Levkovitz, prof. 972-9-7478644 firstname.lastname@example.org|
|Principal Investigator:||Yechiel Levkovitz, MD, PhD||Shalvata MHC|